Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday’s episode of her podcast, “Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is ...

This new article publication from Acta Pharmaceutica Sinica B, discusses the use of in situ tumor vaccine with optimized nanoadjuvants and lymph node targeting capacity to treat ovarian cancer and ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is typically ...

Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer cells in patients' blood, research from the University of Michigan and the ...

Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting ...

In this study, researchers aimed to examine trends in nonsurgical management and other treatment modalities in low-risk, HR-positive DCIS.

A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to tumor cells to guide immune cell attacks, overcoming the limitations of ...